Get the Stockscreener App
11.17
3.91%
0.42
After Hours:
11.00
-0.17
-1.52%
Kura Oncology Inc stock is traded at $11.17, with a volume of 5.01M.
It is up +3.91% in the last 24 hours and down -36.21% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
See More
Previous Close:
$10.75
Open:
$10.89
24h Volume:
5.01M
Relative Volume:
4.66
Market Cap:
$818.94M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-5.4488
EPS:
-2.05
Net Cash Flow:
$-138.01M
1W Performance:
-29.79%
1M Performance:
-36.21%
6M Performance:
-47.24%
1Y Performance:
+20.63%
1-Day Range:
$10.71
$11.44
1-Week Range:
$9.68
$12.24
52-Week Range:
$9.06
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
11.17 | 818.94M | 0 | -168.09M | -138.01M | -2.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
How to Take Advantage of moves in (KURA) - Stock Traders Daily
Kura Oncology's SWOT analysis: precision cancer drug stock faces pivotal year - Investing.com Canada
Kura, Kyowa Kirin to co-develop ziftomenib in $1.49B deal - BioWorld Online
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit - The Manila Times
Jefferies Financial Group Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology (NASDAQ:KURA) Given Buy Rating at TD Cowen - Defense World
FY2025 EPS Estimate for Kura Oncology Raised by Analyst - Defense World
Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
Brokers Offer Predictions for Kura Oncology FY2025 Earnings - MarketBeat
Leerink Partnrs Predicts Stronger Earnings for Kura Oncology - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN
Bank of America Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology partners Kyowa Kirin to advance AML treatment - MSN
Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover - MSN
Kura Oncology (NASDAQ:KURA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Kura Oncology & Kyowa Kirin ink billion dollar deal to develop and commercialise Ziftomenib for acute leukemia treatment - BSA bureau
Stifel cuts Kura Oncology target to $11 from $18, holds rating - Investing.com Canada
Firm Advises Kura Oncology on Global Strategic Collaboration with Kyowa Kirin - Wilson Sonsini
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Kura Oncology Stock Slips Following Collaboration With Kyowa: Retail Turns Extremely Bullish - MSN
Bank of America Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock Price - MarketBeat
Earnings call: Kura Oncology reports on ziptamenib's progress in Q3 By Investing.com - Investing.com South Africa
Earnings call: Kura Oncology reports on ziptamenib's progress in Q3 - Investing.com India
Kura Oncology inks global deal with Kyowa Kirin By Investing.com - Investing.com Nigeria
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin - MedCity News
Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn
Kura Oncology: A Contender In The Field Of Precision Medicine - Seeking Alpha
Kura Oncology shares hold Buy rating after Kyowa Kirin deal By Investing.com - Investing.com Canada
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings - Benzinga
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Kura Oncology tumbles as Kyowa collaboration seen hitting M&A prospects By Investing.com - Investing.com Canada
Buy rating reiterated for Kura Oncology stock, analyst raises target on ziftomenib advancements - Investing.com Canada
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% - Yahoo! Voices
Biotech Collapses 27% After Slamming The Door On A Takeover - Investor's Business Daily
HC Wainwright Forecasts Strong Price Appreciation for Kura Oncology (NASDAQ:KURA) Stock - MarketBeat
Kura Signs Leukemia Pact with Kyowa Kirin After Losing Race to Syndax - BioSpace
Kura Oncology inks global deal with Kyowa Kirin - Investing.com
Kura and Kyowa Kirin sign ziftomenib deal - The Pharma Letter
Kura partners with Kyowa Kirin to advance AML treatment - Pharmaceutical Technology
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias - Barchart
Kura stock slides 17% on Kyowa Kirin deal for ziftomenib - MSN
Kura Oncology Shares Fall 14% on Plans for Cancer-Drug Collaboration - MarketWatch
KURAKura Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy - Reuters
Kura Oncology (NASDAQ:KURA) Cut to Sell at StockNews.com - MarketBeat
Kura Oncology's (KURA) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
First Week of KURA July 2025 Options Trading - Nasdaq
Kura Oncology stock gains spotlight amid Revuforj's FDA approval By Investing.com - Investing.com UK
Objective long/short (KURA) Report - Stock Traders Daily
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):